In this podcast, Dr. Briggs talk with Brendon Neuen about his paper in the December issue of JASN. His meta-analysis of the CREDENCE and EMPA-CKD clinical trials - shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.
